FR2861076B1 - Derives de n-heterocyclymethylbenzamide, leur preparation et leur application en therapeutique - Google Patents

Derives de n-heterocyclymethylbenzamide, leur preparation et leur application en therapeutique

Info

Publication number
FR2861076B1
FR2861076B1 FR0312165A FR0312165A FR2861076B1 FR 2861076 B1 FR2861076 B1 FR 2861076B1 FR 0312165 A FR0312165 A FR 0312165A FR 0312165 A FR0312165 A FR 0312165A FR 2861076 B1 FR2861076 B1 FR 2861076B1
Authority
FR
France
Prior art keywords
alkoxy
alkyl
nhso
halo
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0312165A
Other languages
English (en)
French (fr)
Other versions
FR2861076A1 (fr
Inventor
Gihad Dargazanli
Bouhtou Genevieve Estenne
Pascale Magat
Benoit Marabout
Pierre Roger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0312165A priority Critical patent/FR2861076B1/fr
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Priority to EP04791554A priority patent/EP1680421B1/fr
Priority to RU2006116889/04A priority patent/RU2346945C2/ru
Priority to RS20060314A priority patent/RS51587B/sr
Priority to NZ547163A priority patent/NZ547163A/en
Priority to AT04791554T priority patent/ATE386036T1/de
Priority to JP2006534800A priority patent/JP4853918B2/ja
Priority to CN2004800335688A priority patent/CN1882587B/zh
Priority to OA1200600127A priority patent/OA13317A/fr
Priority to PT04791554T priority patent/PT1680421E/pt
Priority to SG200807634-1A priority patent/SG147435A1/en
Priority to HR20080186T priority patent/HRP20080186T3/xx
Priority to MEP-2008-122A priority patent/ME00111B/me
Priority to ES04791554T priority patent/ES2300837T3/es
Priority to ZA200603861A priority patent/ZA200603861B/en
Priority to KR1020067007370A priority patent/KR101125305B1/ko
Priority to PL04791554T priority patent/PL1680421T3/pl
Priority to YUP-2006/0314A priority patent/RS20060314A/sr
Priority to PCT/FR2004/002643 priority patent/WO2005037783A2/fr
Priority to CN2009101638818A priority patent/CN101684118B/zh
Priority to DK04791554T priority patent/DK1680421T3/da
Priority to HK07104714.0A priority patent/HK1098465B/xx
Priority to SI200430687T priority patent/SI1680421T1/sl
Priority to DE602004011806T priority patent/DE602004011806T2/de
Priority to BRPI0415489-4A priority patent/BRPI0415489A/pt
Priority to UAA200605374A priority patent/UA81186C2/uk
Priority to CA2542647A priority patent/CA2542647C/fr
Priority to AU2004281217A priority patent/AU2004281217B2/en
Publication of FR2861076A1 publication Critical patent/FR2861076A1/fr
Application granted granted Critical
Publication of FR2861076B1 publication Critical patent/FR2861076B1/fr
Priority to IL174940A priority patent/IL174940A/en
Priority to US11/404,273 priority patent/US7288656B2/en
Priority to MA28944A priority patent/MA28099A1/fr
Priority to TNP2006000110A priority patent/TNSN06110A1/fr
Priority to EC2006006511A priority patent/ECSP066511A/es
Priority to CR8342A priority patent/CR8342A/es
Priority to NO20062030A priority patent/NO335462B1/no
Priority to HK10109250.4A priority patent/HK1142887B/xx
Priority to US11/858,436 priority patent/US7619089B2/en
Priority to CY20081100494T priority patent/CY1108925T1/el
Priority to US12/573,470 priority patent/US8513246B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
FR0312165A 2003-10-17 2003-10-17 Derives de n-heterocyclymethylbenzamide, leur preparation et leur application en therapeutique Expired - Lifetime FR2861076B1 (fr)

Priority Applications (39)

Application Number Priority Date Filing Date Title
FR0312165A FR2861076B1 (fr) 2003-10-17 2003-10-17 Derives de n-heterocyclymethylbenzamide, leur preparation et leur application en therapeutique
HK07104714.0A HK1098465B (en) 2003-10-17 2004-10-15 Use of tricyclic compounds as glycine transport inhibitors
RS20060314A RS51587B (sr) 2003-10-17 2004-10-15 Derivati n-heterociklilmetilbenzamida, postupak za njihovo dobijanje i njihova upotreba kao leka
NZ547163A NZ547163A (en) 2003-10-17 2004-10-15 Derivatives of N-heterocyclylmethylbenzamides, preparation method thereof and application of therapeutics as glycine transport inhibitors
AT04791554T ATE386036T1 (de) 2003-10-17 2004-10-15 Verwendung tricyclischer verbindungen als inhibitoren des glycintransports
JP2006534800A JP4853918B2 (ja) 2003-10-17 2004-10-15 グリシン輸送阻害剤としての三環式化合物の使用
CN2004800335688A CN1882587B (zh) 2003-10-17 2004-10-15 三环化合物作为甘氨酸转运抑制剂的用途
OA1200600127A OA13317A (fr) 2003-10-17 2004-10-15 Dérivés de N-hétérocyclylméthylbenzamides, leur préparation et leur application en thérapeutique.
PT04791554T PT1680421E (pt) 2003-10-17 2004-10-15 Compostos tricíclicos como inibidores de transporte de glicina
SG200807634-1A SG147435A1 (en) 2003-10-17 2004-10-15 Derivatives of n-heterocyclylmethylbenzamides, preparation method thereof and application of same in therapeutics
HR20080186T HRP20080186T3 (en) 2003-10-17 2004-10-15 Use of tricyclic compounds as glycine transport inhibitors
MEP-2008-122A ME00111B (me) 2003-10-17 2004-10-15 Derivati n-heterociklilmetilbenzamida, postupak za njihovo dobijanje i njihova upotreba kao lijeka
ES04791554T ES2300837T3 (es) 2003-10-17 2004-10-15 Compuestos triciclicos como inhibidores de transporte de glicina.
ZA200603861A ZA200603861B (en) 2003-10-17 2004-10-15 Use of tricyclic compounds as glycine transport inhibitors
KR1020067007370A KR101125305B1 (ko) 2003-10-17 2004-10-15 Ｎ-헤테로시클릴메틸벤즈아미드의 유도체, 그의 제조 방법및 치료에 있어서 그의 적용
PL04791554T PL1680421T3 (pl) 2003-10-17 2004-10-15 Związki trycykliczne jako inhibitory transportu glicyny
YUP-2006/0314A RS20060314A (sr) 2003-10-17 2004-10-15 Derivati n-heterociklilmetilbenzamida, postupak za njihovo dobijanje i njihova upotreba kao leka
DE602004011806T DE602004011806T2 (de) 2003-10-17 2004-10-15 Verwendung tricyclischer verbindungen als inhibitoren des glycintransports
CN2009101638818A CN101684118B (zh) 2003-10-17 2004-10-15 三环化合物作为甘氨酸转运抑制剂的用途
DK04791554T DK1680421T3 (da) 2003-10-17 2004-10-15 Tricykliske forbindelser som inhibitorer af glycintransport
EP04791554A EP1680421B1 (fr) 2003-10-17 2004-10-15 Composes tricycliques comme inhibiteurs de transport de glycine
PCT/FR2004/002643 WO2005037783A2 (fr) 2003-10-17 2004-10-15 Composes tricycliques comme inhibiteurs de transport de glycine
RU2006116889/04A RU2346945C2 (ru) 2003-10-17 2004-10-15 Производные n-гетероциклилметилбензамидов, их получение и их применение в терапии
BRPI0415489-4A BRPI0415489A (pt) 2003-10-17 2004-10-15 derivados de n-heterociclilmetilbenzamidas, sua preparação e sua aplicação em terapêutica
UAA200605374A UA81186C2 (en) 2003-10-17 2004-10-15 N-heterocyclylmethyl benzamide derivatives, preparation thereof and use in therapy
CA2542647A CA2542647C (fr) 2003-10-17 2004-10-15 Derives de n-heterocyclylmethylbenzamides, leur preparation et leur application en therapeutique
AU2004281217A AU2004281217B2 (en) 2003-10-17 2004-10-15 Use of tricyclic compounds as glycine transport inhibitors
SI200430687T SI1680421T1 (sl) 2003-10-17 2004-10-15 Uporaba tricikličnih spojin kot inhibitorji glicinskega transporta
IL174940A IL174940A (en) 2003-10-17 2006-04-11 Derivatives of n-heterocyclylmethylbenzamides, preparation method thereof and application of same in therapeutics
US11/404,273 US7288656B2 (en) 2003-10-17 2006-04-14 Derivatives of N-heterocyclylmethylbenzamides, preparation method thereof and application of same in therapeutics
EC2006006511A ECSP066511A (es) 2003-10-17 2006-04-17 Derivados de n-heterociclilmetilbenzamidas, su preparación y su aplicación en terapeutica
MA28944A MA28099A1 (fr) 2003-10-17 2006-04-17 Derives de n-heterocyclymethylbenzamides, leur preparation et leur application en therapeutique
TNP2006000110A TNSN06110A1 (fr) 2003-10-17 2006-04-17 Composes tricycliques comme inhibiteurs de transport de glycine
CR8342A CR8342A (es) 2003-10-17 2006-04-18 Derivados de n-heterociclimetilbenzamidas, su preparacion y su aplicacion en terapeutica
NO20062030A NO335462B1 (no) 2003-10-17 2006-05-05 Derivater av N-heterocyklylmetylbenzamider, medikament og farmasøytisk preparat inneholdende en slik forbindelse samt anvendelse av forbindelsen
HK10109250.4A HK1142887B (en) 2003-10-17 2007-05-03 Use of tricyclic compounds as glycine transport inhibitors
US11/858,436 US7619089B2 (en) 2003-10-17 2007-09-20 Derivatives of N-heterocyclylmethylbenzamides, preparation method thereof and application of same in therapeutics
CY20081100494T CY1108925T1 (el) 2003-10-17 2008-05-12 Τρικυκλικες ενωσεις ως αναστολεις της μεταφορας γλυκινης
US12/573,470 US8513246B2 (en) 2003-10-17 2009-10-05 Use of N-heterocyclylmethylbenzamides in therapeutics

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0312165A FR2861076B1 (fr) 2003-10-17 2003-10-17 Derives de n-heterocyclymethylbenzamide, leur preparation et leur application en therapeutique

Publications (2)

Publication Number Publication Date
FR2861076A1 FR2861076A1 (fr) 2005-04-22
FR2861076B1 true FR2861076B1 (fr) 2006-01-06

Family

ID=34385252

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0312165A Expired - Lifetime FR2861076B1 (fr) 2003-10-17 2003-10-17 Derives de n-heterocyclymethylbenzamide, leur preparation et leur application en therapeutique

Country Status (32)

Country Link
US (3) US7288656B2 (cg-RX-API-DMAC7.html)
EP (1) EP1680421B1 (cg-RX-API-DMAC7.html)
JP (1) JP4853918B2 (cg-RX-API-DMAC7.html)
KR (1) KR101125305B1 (cg-RX-API-DMAC7.html)
CN (2) CN1882587B (cg-RX-API-DMAC7.html)
AT (1) ATE386036T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004281217B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0415489A (cg-RX-API-DMAC7.html)
CA (1) CA2542647C (cg-RX-API-DMAC7.html)
CR (1) CR8342A (cg-RX-API-DMAC7.html)
CY (1) CY1108925T1 (cg-RX-API-DMAC7.html)
DE (1) DE602004011806T2 (cg-RX-API-DMAC7.html)
DK (1) DK1680421T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP066511A (cg-RX-API-DMAC7.html)
ES (1) ES2300837T3 (cg-RX-API-DMAC7.html)
FR (1) FR2861076B1 (cg-RX-API-DMAC7.html)
HR (1) HRP20080186T3 (cg-RX-API-DMAC7.html)
IL (1) IL174940A (cg-RX-API-DMAC7.html)
MA (1) MA28099A1 (cg-RX-API-DMAC7.html)
ME (1) ME00111B (cg-RX-API-DMAC7.html)
NO (1) NO335462B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ547163A (cg-RX-API-DMAC7.html)
OA (1) OA13317A (cg-RX-API-DMAC7.html)
PL (1) PL1680421T3 (cg-RX-API-DMAC7.html)
PT (1) PT1680421E (cg-RX-API-DMAC7.html)
RS (2) RS20060314A (cg-RX-API-DMAC7.html)
RU (1) RU2346945C2 (cg-RX-API-DMAC7.html)
SG (1) SG147435A1 (cg-RX-API-DMAC7.html)
TN (1) TNSN06110A1 (cg-RX-API-DMAC7.html)
UA (1) UA81186C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005037783A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200603861B (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2842804B1 (fr) 2002-07-29 2004-09-03 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861071B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(alkylpiperidin-2-yl) methyl]benzamide, leur prepartation et leur application en therapeutique
FR2861074B1 (fr) * 2003-10-17 2006-04-07 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861076B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-heterocyclymethylbenzamide, leur preparation et leur application en therapeutique
JP2007530664A (ja) * 2004-03-30 2007-11-01 ペインセプター ファーマ コーポレーション ゲートイオンチャンネルを調節するための組成物及び方法
FR2906251B1 (fr) * 2006-09-22 2008-11-07 Sanofi Aventis Sa Derives de pyrrolizine, indolizine et quinolizine, leur preparation et leur application en therapeutique
US11817637B2 (en) 2006-11-18 2023-11-14 Rfmicron, Inc. Radio frequency identification (RFID) moisture tag(s) and sensors with extended sensing via capillaries
US9582981B2 (en) 2014-10-08 2017-02-28 Rfmicron, Inc. Radio frequency identification (RFID) moisture tag(s) and sensors with extended sensing via capillaries
TW200911808A (en) * 2007-07-23 2009-03-16 Astrazeneca Ab Novel compounds
MX2009014235A (es) 2007-08-22 2010-04-27 Abbott Gmbh & Co Kg 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso.
ES2397764T3 (es) 2008-04-01 2013-03-11 Abbott Gmbh & Co. Kg Tetrahidroisoquinolinas, composiciones farmacéuticas que las contienen, y su uso en terapia
BRPI0922787A2 (pt) * 2008-12-04 2017-07-11 Sanofi Sa Formas polimórficas de um derivado da azabiciclo-trifluorometil benzamida
JP2012516326A (ja) * 2009-01-28 2012-07-19 アストラゼネカ・アクチエボラーグ ２−アザ−ビシクロ［２．２．１］ヘプタン化合物及びそれらの使用
WO2010087761A1 (en) * 2009-01-28 2010-08-05 Astrazeneca Ab 2-aza-bicyclo[2.2.2]octane compounds and uses thereof
FR2941954B1 (fr) * 2009-02-10 2011-04-08 Sanofi Aventis Derives de n-°(6-aza-bicyclo°3.2.1!oct-1-yl)-aryl-methyl! benzamide, leur preparation et leur application en therapeutique
FR2941953B1 (fr) * 2009-02-10 2011-04-08 Sanofi Aventis Derives de n-°(2-aza-bicyclo°2.1.1!hex-1-yl)-benzamide, leur preparation et leur application en therapeutique
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
FR2943059A1 (fr) * 2009-03-16 2010-09-17 Sanofi Aventis Derives de n-°6-aza-bicyclo°3.2.1!oct-5-yl)-aryl-methyl!- heterobenzamide,leur preparation et leur application en therapeutique
FR2943056A1 (fr) * 2009-03-16 2010-09-17 Sanofi Aventis Derives de n-°2-aza-bicyclo°2.1.1!hex-1-yl)-aryl-methyl!- heterobenzamide, leur preparation et leur application en therapeutique
RU2011141778A (ru) * 2009-03-16 2013-04-27 Санофи Производные n-[(2-азабицикло[2.1.1]гекс-1-ил)арилметил]гетеробензамида, их получение и их применение в терапии
FR2944284A1 (fr) * 2009-04-14 2010-10-15 Sanofi Aventis Derives de n-°7-aza-bicyclo°2.2.1!hept-1-yl)-aryl-methyl! -benzamide, leur preparation et leur application en therapeutique
US8153653B2 (en) 2010-06-22 2012-04-10 Hoffmann-La Roche Inc. Amido-tropane derivatives
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) * 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013020930A1 (en) 2011-08-05 2013-02-14 Abbott Gmbh & Co. Kg Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013072520A1 (en) 2011-11-18 2013-05-23 AbbVie Deutschland GmbH & Co. KG N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
TR201806764T4 (tr) * 2011-11-29 2018-06-21 Vivozon Inc Yeni benzamid türevi ve bunun kullanımı.
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
KR20160062164A (ko) 2013-10-17 2016-06-01 아비에 도이치란트 게엠베하 운트 콤파니 카게 아미노크로만, 아미노티오크로만 및 아미노-1,2,3,4-테트라하이드로퀴놀린 유도체, 이들을 포함하는 약제학적 조성물, 및 치료에서 이들의 용도
CA2924699A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
JP6906227B2 (ja) * 2017-08-18 2021-07-21 国立大学法人千葉大学 ハロゲン結合ドナー／有機塩基複合型化合物及び酸塩基複合触媒

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4066662A (en) * 1973-12-14 1978-01-03 Science Union Et Cie., Societe Francaise De Recherche Medicale N-substituted-2-aminomethyl-3-azabicyclo(3,3,0)octane compounds
CA1223873A (en) * 1982-04-14 1987-07-07 Francis D. King Pharmaceutically active compounds
ES2051753T3 (es) * 1986-12-16 1994-07-01 Robins Co Inc A H N-(1-azabiciclo(2.2.2)octo-3-il) benzamidas y tiobenzamidas ansioliticas.
GB8720805D0 (en) * 1987-09-04 1987-10-14 Naylor R J 2-alkoxy-n-(1-azabicyclo(2 2 2)oct-3-yl)benzamides & thiobenzamides
SE9600683D0 (sv) * 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
EP1058684A1 (en) * 1998-03-06 2000-12-13 Janssen Pharmaceutica N.V. Glycine transport inhibitors
FR2861076B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-heterocyclymethylbenzamide, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
CA2542647A1 (fr) 2005-04-28
US7619089B2 (en) 2009-11-17
PL1680421T3 (pl) 2008-07-31
CN1882587A (zh) 2006-12-20
PT1680421E (pt) 2008-05-13
FR2861076A1 (fr) 2005-04-22
RU2346945C2 (ru) 2009-02-20
CA2542647C (fr) 2012-07-10
TNSN06110A1 (fr) 2007-11-15
CN1882587B (zh) 2012-06-27
KR20060109432A (ko) 2006-10-20
JP2007508361A (ja) 2007-04-05
ECSP066511A (es) 2006-10-10
WO2005037783A3 (fr) 2005-07-07
AU2004281217B2 (en) 2010-07-22
SG147435A1 (en) 2008-11-28
BRPI0415489A (pt) 2006-12-26
US20060264441A1 (en) 2006-11-23
ZA200603861B (en) 2007-12-27
KR101125305B1 (ko) 2012-03-27
EP1680421B1 (fr) 2008-02-13
CN101684118B (zh) 2013-04-10
US20100022548A1 (en) 2010-01-28
DE602004011806D1 (de) 2008-03-27
NZ547163A (en) 2010-01-29
UA81186C2 (en) 2007-12-10
CY1108925T1 (el) 2014-07-02
CR8342A (es) 2006-10-04
DE602004011806T2 (de) 2009-02-05
HK1098465A1 (en) 2007-07-20
HRP20080186T3 (en) 2008-05-31
IL174940A (en) 2010-11-30
OA13317A (fr) 2007-04-13
ES2300837T3 (es) 2008-06-16
ATE386036T1 (de) 2008-03-15
ME00111B (me) 2010-10-10
JP4853918B2 (ja) 2012-01-11
NO20062030L (no) 2006-07-07
MEP12208A (en) 2010-06-10
CN101684118A (zh) 2010-03-31
RU2006116889A (ru) 2007-11-27
IL174940A0 (en) 2006-08-20
US7288656B2 (en) 2007-10-30
AU2004281217A1 (en) 2005-04-28
HK1142887A1 (en) 2010-12-17
MA28099A1 (fr) 2006-08-01
NO335462B1 (no) 2014-12-15
RS51587B (sr) 2011-08-31
US20080070941A1 (en) 2008-03-20
RS20060314A (sr) 2008-08-07
WO2005037783A2 (fr) 2005-04-28
EP1680421A2 (fr) 2006-07-19
DK1680421T3 (da) 2008-06-09
US8513246B2 (en) 2013-08-20

Similar Documents

Publication Publication Date Title
FR2861076B1 (fr) Derives de n-heterocyclymethylbenzamide, leur preparation et leur application en therapeutique
PL1680418T3 (pl) Pochodne N-[heteroarylo(piperydyn-2-ylo)metylo]benzamidu, ich wytwarzanie i zastosowanie ich w lecznictwie
IL174936A0 (en) Derivatives of n-[phenyl(alkylpiperidine-2-yl) methyl] benzamide, prearation method thereof and application of same in therapeutics
NO945084D0 (no) Substituerte heterocykliske karboksylsyreamider, deres fremstilling og anvendelse som legemiddel
NO944162L (no) Substituerte heterosykliske karboksylsyreamider, deres fremstilling og deres anvendelse som legemiddel
IL189183A0 (en) Novel indole compounds
WO2002010154A3 (en) Substituted heterocyclic amides
RU2006101553A (ru) Новые соединения, которые модулируют рецепторы типа ppary, и их применение в косметических и фармацевтических композициях
ATE396189T1 (de) Cyanopyrrolhaltige cyclische carbamat- und thiocarbamatbiaryle und verfahren zu deren herstellung
ATE347887T1 (de) Arzneimittel enthaltend substituierte 2-aryl- aminoessigsäure-verbindungen und/oder substituierte 2-heteroaryl-aminoessigsäure- verbindungen
RU2002132380A (ru) Новые соединения
TH93950A (th) อนุพันธ์ 1,4-เบนไซโธอีพีน 1,1- ไดออกไซด์ชนิดใหม่ ที่แทนที่โดยเบนซิลแรดิคัล, วิธีสำหรับการเตรียมสารนั้น, เภสัชภัณฑ์ซึ่งประกอบรวมด้วยสารประกอบเหล่านี้และการใช้สารนั้น

Legal Events

Date Code Title Description
CD Change of name or company name
PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15